Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...
CPC review of 5,000 sales finds Compass at 29.7% to 39.5% share in five metros, raising double-ending and private listing ...
The Consumer Policy Center estimated that Compass’ market share was up to 40 percent after its deal for Anywhere Real Estate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results